Alexion stock rises 1.4% after naming new executives -- MarketWatch
June 02 2017 - 11:03AM
Dow Jones News
Alexion Pharmaceuticals Inc. (ALXN) shares rose 1.4% to $101.57
in morning trade Friday, after the company announced several new
executives will start June 5. The news follows a at the
biopharmaceutical company in late May, in which Alexion announced
the departures of its chief commercial officer, chief financial
officer -- who started at the company in December -- and two
executive vice presidents. The company has faced a scandal over
sales practices for its expensive blood disorder medication
Soliris. Alexion named John Orloff, who previously served as
executive vice president at Novelion Therapeutics Inc. (NVLN), as
its head of research and development, and named Anne-Marie Law, who
previously served as chief human resources officer at Hyatt Hotels
Corporation (H), as the new chief human resources officer. Alexion
also named Indrani Lall Franchini, previously chief compliance
officer at Hess Corporation (HES), as its new chief compliance
officer. Alexion shares have dropped 23.5% over the last three
months, compared with with a 2% rise in the S&P 500 .
-MarketWatch
For more from MarketWatch: http://www.marketwatch.com/newsviewer
(END) Dow Jones Newswires
June 02, 2017 10:48 ET (14:48 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Novelion Therapeutics (NASDAQ:NVLN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novelion Therapeutics (NASDAQ:NVLN)
Historical Stock Chart
From Apr 2023 to Apr 2024